Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $5.2 million.

  • Viridian Therapeutics, Inc.\DE's Non-Current Assets rose 1501.21% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year increase of 269.77%. This contributed to the annual value of $3.9 million for FY2024, which is 10.14% down from last year.
  • Viridian Therapeutics, Inc.\DE's Non-Current Assets amounted to $5.2 million in Q3 2025, which was up 1501.21% from $3.6 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Assets registered a high of $5.2 million during Q3 2025, and its lowest value of $1.3 million during Q1 2021.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Non-Current Assets averaged around $3.8 million, with its median value being $3.8 million (2022).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Non-Current Assets surged by 27921.02% in 2021, and later tumbled by 2213.79% in 2024.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Non-Current Assets stood at $3.5 million in 2021, then grew by 10.49% to $3.9 million in 2022, then rose by 0.71% to $3.9 million in 2023, then dropped by 0.1% to $3.9 million in 2024, then soared by 32.55% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $3.6 million for Q2 2025, and $3.7 million during Q1 2025.